Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LCB01-0371 in Healthy Volunteers
NCT02529241Phase 1Terminated
- Sponsor
- LigaChem Biosciences
- Start
- Jul 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of delpazolid in Tuberculosis (TB) (2 arms), sponsored by LigaChem Biosciences. Primary endpoints: Peak Plasma Concentration at 24 hours, Time to Maximum Concentration at 24 hours and 1 more. Started Jul 2015; status: terminated.
02
Drugs
delpazolid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02529241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02529241.